Metformin Moderately Reduces Antipsychotic-Related Weight Gain in Youth with Bipolar Spectrum Disorders: Large Pragmatic 24‑Month Trial Supports Clinical Use

Metformin Moderately Reduces Antipsychotic-Related Weight Gain in Youth with Bipolar Spectrum Disorders: Large Pragmatic 24‑Month Trial Supports Clinical Use

A 1,565‑participant pragmatic randomized trial shows metformin added to lifestyle counseling produced modest but statistically significant reductions in BMI Z-score at 6 and 24 months in overweight/obese children and adolescents with bipolar spectrum disorders taking second‑generation antipsychotics.
Metformin Modestly Reduces Antipsychotic-Associated Weight Gain in Youth with Bipolar Spectrum Disorders — Large Pragmatic Trial Supports Consideration in Practice

Metformin Modestly Reduces Antipsychotic-Associated Weight Gain in Youth with Bipolar Spectrum Disorders — Large Pragmatic Trial Supports Consideration in Practice

A large, pragmatic randomized trial found that adjunctive metformin produced a modest but statistically significant reduction in BMI Z-score at 6 and 24 months among overweight and obese youth with bipolar spectrum disorders treated with second-generation antipsychotics.
Optimizing Gonorrhea and Chlamydia Screening for Adolescents in Emergency Departments: Evidence from Targeted and Universal Strategies

Optimizing Gonorrhea and Chlamydia Screening for Adolescents in Emergency Departments: Evidence from Targeted and Universal Strategies

Comparative effectiveness evidence from multicenter pediatric emergency departments demonstrates that targeted and universally offered gonorrhea and chlamydia screening increase detection rates versus usual care, highlighting the need for integrated ED screening protocols in adolescents.